Saluda Medical Evoke SCS System
Saluda Medical Pty, Ltd. · Decision date Oct 16, 2026
What did the FDA decide?
The FDA record P190002/S052 is a 30-Day Notice supplement to PMA P190002 for the Saluda Medical Evoke SCS System, filed under the reason Process Change - Manufacturer/Sterilizer/Packager/Supplier. The reported statement describes approval of additional sterilization chambers at one of Saluda's contract manufacturers. It does not describe a change to the stimulator itself or to its labeled indications.
The S supplement number links this action to the original P190002 approval, but it is a manufacturing-process notice, not a new approval of the whole device. The record does not identify the contract manufacturer, the number or location of added chambers, the sterilization method, or any validation data. The stated purpose of adding sterilization capacity is not independent evidence of safety or clinical effectiveness; those determinations are not established by this entry.
Whether the added chambers alter sterilization parameters or only capacity is absent from the supplied fields, so that distinction cannot be settled here.
FDA approval order statement
approval of additional sterilization chambers at one of Saludas contract manufacturers
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Neurology
- Decision date
- Oct 16, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P190002/S052
- Regulatory pathway
- PMA supplement
- Applicant
- Saluda Medical Pty, Ltd.
- Product code
- LGW
- Decision code
- OK30
- Decision date
- Oct 16, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Stimulator, spinal-cord, totally implanted for pain relief.
- Applicant
- Saluda Medical Pty, Ltd.
- Product code
- LGW
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P190002. Subsequent supplements may change the device or its indications.
FDA decision timeline
P190002 · Original PMA
Saluda Medical Evoke SCS System
P190002/S052 received
Application receipt date recorded by FDA.
P190002/S051 · Related supplement
Saluda Medical Evoke SCS System
P190002/S052 · FDA decision
30-Day Notice
Timeline entries are records held by MedtechLedger for P190002. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P190002
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Saluda Medical Pty, Ltd. | PMA approval | Feb 28, 2022 | FDA | |
Saluda Medical Evoke SCS SystemP190002/S051 | Saluda Medical Pty, Ltd. | PMA supplement | Oct 15, 2026 | FDA |
Explore the linked device profile
Other records with product code LGW
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| ABBOTT MEDICAL | PMA supplement | Oct 30, 2026 | FDA | |
| ABBOTT MEDICAL | PMA supplement | Oct 30, 2026 | FDA | |
| Medtronic Neuromodulation | PMA supplement | Oct 30, 2026 | FDA | |
| Medtronic Neuromodulation | PMA supplement | Oct 29, 2026 | FDA | |
| ABBOTT MEDICAL | PMA supplement | Oct 28, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Saluda Medical Pty, Ltd.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Level 1, 407 Pacific Hwy., Atarmon, NSW 2064
Sources and methodology
- Original FDA record: P190002/S052
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records



